Using rifaximin to improve liver transplant outcomes
Effect of Perioperative Oral Rifaximin on Early Graft Dysfunction in Adult Living Donor Liver Transplant: An Open Label Randomized Control Trial
This study is testing if taking the antibiotic rifaximin before and after liver transplant surgery can help prevent early problems with the new liver in adults.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Institute of Liver and Biliary Sciences, India Academic / other |
| Locations | 1 site (New Delhi, National Capital Territory of Delhi) |
| Trial ID | NCT06743464 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effect of perioperative oral rifaximin on early graft dysfunction in adult patients undergoing living donor liver transplantation. The study involves administering rifaximin 550 mg twice daily starting two weeks before surgery and continuing until one week post-operation. It aims to determine whether this antibiotic can reduce the incidence of early graft dysfunction, which is a significant complication associated with liver transplants. The trial will include 100 participants and is designed as an open-label randomized control study.
Who should consider this trial
Good fit: Ideal candidates for this study are adult patients scheduled for living donor liver transplantation.
Not a fit: Patients who are undergoing retransplantation or have acute liver failure or acute-on-chronic liver failure will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly reduce early graft dysfunction and improve survival rates for liver transplant recipients.
How similar studies have performed: Previous studies have shown that rifaximin can reduce early graft dysfunction in deceased donor liver transplants, suggesting potential for success in this living donor context.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All recipients (adults) undergoing living donor liver transplant in ILBS. Exclusion Criteria: * Negative consent * Hypersensitivity to Rifaximin * Patients undergoing retransplant * ALF, ACLF * Pediatrics patients * Patients on rifaximin
Where this trial is running
New Delhi, National Capital Territory of Delhi
- Insitute of Liver and Biliary Sciences — New Delhi, National Capital Territory of Delhi, India (Recruiting)
Study contacts
- Study coordinator: Tapan Kumar Pradhan, MS
- Email: tapan.ravi94@gmail.com
- Phone: 9970189001
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.